Vertex Pharmaceuticals (VRTX)

NasdaqGS: VRTX · 即時價格 · USD

515.44

+0.88 (0.17%)

收盤價： Sep 11, 2026, 3:59 PM

514.51

-0.18%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

0.17% (1D)

買價	516.23
市值	131B
營收 (ttm)	12.6B
淨利（ttm）	4.41B
	0.32
	17.19
	29.98
	25.6
P/B (ttm)	6.45
P/S (ttm)	10.37
財報日期	Nov 2, 2026

賣價	529.62
成交量	831,098
20 日平均成交量	1,479,617
開盤價	522.10
前收盤價	514.56
當日區間	511.81 - 522.10
52 週範圍	374.17 - 560.25
分析師	購買
目標價	575 (11.56%)
股利	n/a
除息日	n/a

關於 VRTX

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 24, 1991

員工 6,400

證券交易所 NasdaqGS

股票代號 VRTX

網站 https://www.vrtx.com

完整的公司簡介

財務表現

Vertex Pharmaceuticals 在 2025 年的營收為 12B，較前一年的 11.02B 增加 8.9%。淨利為 3.95B，較前期減少 -838.09%。

財務報表

分析師預測

根據 27 位分析師的評等，VRTX 的平均評等為「Buy」。12 個月目標價為 575，較最新價格有 11.56% 的上漲空間。

股票預測

財報驚奇

Vertex Pharmaceuticals 已於 Aug 3, 2026 公布季度財報：

營收為 $3.33B 低於預期 $0, 年增 12.45% 成長.
每股盈餘為 4.73 低於預期 -0.02, 年增 4.65% 成長.

下次財報發布

Vertex Pharmaceuticals 的下次財報預計於 Nov 2, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

5 小時前 · Insider Monkey

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gi...

14 小時前 · FX Empire

Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.

16 小時前 · Motley Fool

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September

Both companies are approaching milestones that could light a fire under their stocks.

1 日前 · StockStory

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.

3 天前 · Motley Fool

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

The company has tremendous prospects.

第 1 頁，共 2 頁

Vertex Pharmaceuticals (VRTX)